NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $19.00 target price on the stock.

NRXP has been the topic of several other reports. D. Boral Capital reissued a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a research note on Monday. Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd.

NRx Pharmaceuticals Stock Down 0.9 %

Shares of NRx Pharmaceuticals stock opened at $2.18 on Thursday. The company’s fifty day simple moving average is $2.91 and its two-hundred day simple moving average is $2.03. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a market cap of $36.88 million, a PE ratio of -1.02 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, sell-side analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NRXP. Townsquare Capital LLC purchased a new position in shares of NRx Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Sassicaia Capital Advisers LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter worth $33,000. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter valued at about $56,000. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals during the fourth quarter valued at approximately $61,000. Finally, Anson Funds Management LP purchased a new stake in NRx Pharmaceuticals during the 3rd quarter valued at $241,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.